tiprankstipranks
Trending News
More News >
Passage Bio (PASG)
NASDAQ:PASG
US Market

Passage Bio (PASG) AI Stock Analysis

Compare
541 Followers

Top Page

PA

Passage Bio

(NASDAQ:PASG)

Rating:44Neutral
Price Target:
Passage Bio scores moderately low due to its financial challenges, including no revenue and significant cash burn. However, a strong balance sheet and recent corporate event announcements, including program advancements and extended cash runway, provide some optimism. Technical indicators suggest a neutral to bearish sentiment, and traditional valuation metrics are limited due to the company's stage and lack of profitability.
Positive Factors
Clinical Data
Updates from the ongoing Ph1/2 study of PBFT02 in GRN-FTD patients showed sustained PGRN expression and importantly, an approximately 13% reduction in plasma NfL levels, an FDA-accepted surrogate endpoint for accelerated approval.
Financial Stability
Extended cash runway into 1Q27 suggests financial stability and potential for further developments.
Manufacturing Process
The new suspension-based manufacturing process and alignment with the FDA on the potency assay are positive steps towards clinical and commercial success.
Negative Factors
Event Timing
Patient dosing in Cohort 3, most likely at the same Dose 2, will continue after an independent DMC review of available safety data, although management is not guiding on when dosing will begin and data will be available.
Product Development
The addition of a lower dose is being explored to evaluate the drug's therapeutic window and understand the dose response profile for PBFT02 treatment, with initial cohort 2 data expected to be a key catalyst for PASG.

Passage Bio (PASG) vs. SPDR S&P 500 ETF (SPY)

Passage Bio Business Overview & Revenue Model

Company DescriptionPassage Bio (PASG) is a biotechnology company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disorders. The company specializes in gene therapies, utilizing cutting-edge technologies to address unmet medical needs in neurology. With a robust pipeline of therapies in various stages of development, Passage Bio aims to deliver precision medicine solutions to patients with debilitating genetic conditions.
How the Company Makes MoneyPassage Bio primarily generates revenue through partnerships, collaborations, and licensing agreements with other pharmaceutical and biotechnology companies. These collaborations often involve upfront payments, milestone payments based on the achievement of clinical and regulatory milestones, and royalties on future product sales. The company may also receive government grants and research funding to support its R&D initiatives. Passage Bio's focus on developing gene therapies for rare CNS disorders allows it to target markets with high unmet medical needs, potentially leading to premium pricing for successful therapies. As its products progress through clinical trials and potentially reach commercialization, the company aims to generate revenue from sales of its approved therapies.

Passage Bio Financial Statement Overview

Summary
Passage Bio faces common challenges in the biotech industry, with no revenue and significant cash burn. While the balance sheet shows a reasonable equity base, increasing leverage and persistent net losses pose risks that need careful management as the company develops its pipeline.
Income Statement
15
Very Negative
Passage Bio has not generated any revenue over the past years, which is typical for early-stage biotechnology companies. However, the consistent and significant net losses and negative EBIT margins highlight ongoing financial challenges in achieving profitability.
Balance Sheet
60
Neutral
The company's balance sheet shows a reasonable equity base with an Equity Ratio of approximately 60%. However, the Debt-to-Equity ratio is increasing, indicating rising leverage, which may pose a risk if cash reserves decline further.
Cash Flow
40
Negative
Operating cash flow is consistently negative, reflecting significant cash burn typical of biotech firms in development stages. Free cash flow is also negative, although financing activities have bolstered cash positions, providing some liquidity strength.
Breakdown
TTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
0.000.000.000.000.000.00
Gross Profit
-800.00K-3.08M-3.72M-3.68M-1.54M-800.00K
EBIT
-68.81M-70.40M-108.39M-138.39M-185.73M-112.90M
EBITDA
-58.46M-61.69M-98.34M-128.72M-185.73M-110.10M
Net Income Common Stockholders
-63.46M-64.77M-102.06M-136.13M-185.39M-112.23M
Balance SheetCash, Cash Equivalents and Short-Term Investments
63.36M76.76M114.29M189.61M315.77M304.82M
Total Assets
86.01M102.41M150.54M243.55M355.08M328.01M
Total Debt
25.12M25.48M26.29M27.11M0.000.00
Net Debt
-38.24M-12.10M4.58M-7.49M-128.97M-135.00M
Total Liabilities
39.30M41.15M39.26M42.18M36.42M23.29M
Stockholders Equity
46.71M61.26M111.28M201.37M318.66M304.71M
Cash FlowFree Cash Flow
-42.91M-47.99M-78.41M-123.48M-152.52M-82.17M
Operating Cash Flow
-42.87M-47.96M-78.26M-118.21M-126.88M-80.52M
Investing Cash Flow
69.33M54.95M65.24M25.20M-45.81M-172.11M
Financing Cash Flow
132.00K8.87M135.00K-1.35K166.66K228.75M

Passage Bio Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.39
Price Trends
50DMA
0.37
Positive
100DMA
0.43
Negative
200DMA
0.55
Negative
Market Momentum
MACD
0.02
Positive
RSI
48.04
Neutral
STOCH
26.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PASG, the sentiment is Negative. The current price of 0.39 is below the 20-day moving average (MA) of 0.40, above the 50-day MA of 0.37, and below the 200-day MA of 0.55, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 48.04 is Neutral, neither overbought nor oversold. The STOCH value of 26.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PASG.

Passage Bio Risk Analysis

Passage Bio disclosed 1 risk factors in its most recent earnings report. Passage Bio reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Passage Bio Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$5.37B3.26-45.10%3.30%16.81%0.02%
44
Neutral
$24.74M-70.06%146.47%57.85%
44
Neutral
$24.30M-83.73%42.39%
41
Neutral
$18.49M-161.93%-0.38%
39
Underperform
$27.02M-282.07%-220.54%
35
Underperform
$54.76M-280.78%68.75%
33
Underperform
$22.64M-112.99%57.93%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PASG
Passage Bio
0.39
-0.62
-61.39%
TPST
Tempest Therapeutics
6.61
-31.22
-82.53%
CMMB
Chemomab Therapeutics
1.20
0.35
41.18%
ANVS
Annovis Bio
2.81
-2.70
-49.00%
GBIO
Generation Bio
0.37
-2.55
-87.33%
CGTX
Cognition Therapeutics
0.30
-1.89
-86.30%

Passage Bio Corporate Events

Business Operations and StrategyFinancial Disclosures
Passage Bio Reports 2024 Financial Results and Program Advances
Positive
Mar 4, 2025

On March 4, 2025, Passage Bio reported its financial results for the fourth quarter and full year 2024, highlighting significant advancements in its PBFT02 program for FTD-GRN patients. The company demonstrated promising interim data showing durable progranulin expression and early biomarker improvements, and it plans to expand its clinical trials to include FTD patients with C9orf72 gene mutations. Passage Bio also extended its cash runway into the first quarter of 2027 by adopting an outsourced analytical testing model and reducing operating expenses, positioning itself well for late-stage development and regulatory engagement.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.